Home Cart Sign in  
Chemical Structure| 51012-33-0 Chemical Structure| 51012-33-0

Structure of Tiapride HCl
CAS No.: 51012-33-0

Chemical Structure| 51012-33-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Tiapride HCl is a drug that selectively blocks D2 and D3 dopamine receptors in the brain.

Synonyms: Tiapride Hydrochloride; Tiapride(hydrochloride)

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Tiapride HCl

CAS No. :51012-33-0
Formula : C15H25ClN2O4S
M.W : 364.89
SMILES Code : O=C(NCCN(CC)CC)C1=CC(S(=O)(C)=O)=CC=C1OC.[H]Cl
Synonyms :
Tiapride Hydrochloride; Tiapride(hydrochloride)
MDL No. :MFCD00133861

Safety of Tiapride HCl

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Tiapride HCl

GPCR

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02374567 Dementia Depr... More >>ession Schizophrenia Psychosomatic Disorders Anxiety Disorders Less << Phase 3 Terminated - Germany ... More >> Bezirkskrankenhaus Augsburg Augsburg, Germany Krankenhaus Hedwigshöhe Berlin, Germany Hannover Medical School Hannover, Germany, 30625 Asklepios Fachklinikum Lübben Lübben, Germany Asklepios Fachklinikum Teupitz Teupitz, Germany Less <<
NCT00534573 Clozapine-induced Hypersalivat... More >>ion Less << Phase 3 Completed - Israel ... More >> Be'er Sheva Mental Health Center, Tirat HaKarmel Mental Health Center Be'er Sheva, Haifa, Israel Less <<
NCT01765829 Psychosis Nos/Other Phase 3 Unknown November 2015 Spain ... More >> Mental Health Unit Villamartín Recruiting Villamartín, Cádiz, Spain, 11650 Contact: José María Mongil San Juan, MD    0034956040209    cheman45@gmail.com    Principal Investigator: José María Mongil San Juan, MD          Mental Health Unit Baza Recruiting Baza, Granada, Spain, 18800 Contact: Eva Bravo Barba, MD       eva.bravo.barba@gmail.com    Principal Investigator: Eva Bravo Barba, MD          Mental Health Unit Motril Recruiting Motril, Granada, Spain, 18600 Contact: María Luisa Barrigón Estévez, MD    0034958038849    marial.barrigon.sspa@juntadeandalucia.es    Principal Investigator: María Luisa Barrigón Estévez, MD          Mental Health Unit Andújar Recruiting Andújar, Jaén, Spain, 23740 Contact: Fernando Sarramea Crespo, MD, PhD    0034953021717    fernandosarramea@hotmail.com    Principal Investigator: Farnando Sarramea Crespo, MD, PhD          Mental Health Unit Martos Recruiting Martos, Jaén, Spain, 23600 Contact: Miguel Ortigosa Luque, MD       migueortigosa@hotmail.com    Principal Investigator: Miguel Ortigosa Luque, MD          Mental Health Unit Miraflores Not yet recruiting Alcobendas, Madrid, Spain, 28100 Contact: María Luisa Zamarro Arraz, MD, PhD    0034916530108    zamarroluisa@yahoo.es    Principal Investigator: María Luisa Zamarro Arraz, MD, PhD          Hospital Infanta Sofía Not yet recruiting San Sebastian de los Reyes, Madrid, Spain, 28702 Contact: María Rosario Gutiérrez Labrador, MD       rosagutierrez@psiquiatra.e.telefonica.net    Principal Investigator: María Rosario Guitiérrez Labrador, MD          Mental Health Unit Valle del Guadalhorce Not yet recruiting Cártama, Málaga, Spain, 29580 Contact: Daniel Gutiérrez Castillo, MD    0034951033931    dgutierrezcastillo@gmail.com    Principal Investigator: Daniel Gutiérrez Castillo, MD          Mental Health Unit Las Lagunas Not yet recruiting Fuengiróla, Málaga, Spain, 29650 Contact: María Isabel Osuna Carmona, MD       maribelosunac@hotmail.com    Principal Investigator: María Isabel Osuna Carmona, MD          Fundación Argibide Not yet recruiting Pamplona, Navarra, Spain, 31007 Contact: Ignacio Mata Pastor, MD, PhD    0034948266650    nacho.mata70@gmail.com    Principal Investigator: Ignacio Mata Pastor, MD, PhD          Hospital El Tomillar Recruiting Dos Hermanas, Seville, Spain, 41700 Contact: Joaquín Carlos Martín Muñoz, MD, PhD    0034955016083    joaquinmartin@hotmail.com    Principal Investigator: Joaquín Carlos Martín Muñoz, MD, PhD          Hospital Francesc de Borja Recruiting Gandía, Valencia, Spain, 46700 Contact: María Lacruz Silvestre, MD, PhD       maria.lacruz.silvestre@gmail.com    Principal Investigator: María Lacruz Silvestre, MD, PhD          Hospital de Basurto Not yet recruiting Bilbao, Spain, 48013 Contact: Sonia Bustamante Madariaga, MD, Phd    0034944 006137    sonia.bustamantemadariaga@osakidetza.net    Principal Investigator: Sonia Bustamante Madariaga, MD, PhD          Mental Health Unit Tetuán Not yet recruiting Madrid, Spain, 28003 Contact: Mariano Hernández Monsalve, MD, PhD    0034915347363    hergoico@gmail.com    Contact: Ruth Berdún Pe, MD       ruthberdun@yahoo.es    Principal Investigator: Mariano Hernández Monsalve, MD, PhD          Lafora Hospital Not yet recruiting Madrid, Spain, 28049 Contact: Juan Dios Molina Martín, MD, PhD       jmolinamar@hotmail.com    Principal Investigator: Juan Dios Molina Martín, MD, PhD          Hospital Carlos Haya Recruiting Málaga, Spain, 29009 Contact: Fermín Mayoral Cleríes, Md, PhD       fermin.mayoral.sspa@juntadeandalucia.es    Principal Investigator: Fermín Mayoral Cleríes, MD, PhD          Virgen del Rocío Hospital Recruiting Seville, Spain, 41013 Contact: Clara M. Rosso Fernández, MD    0034955013414    claram.rosso.sspa@juntadeandalucia.es    Contact: Miguel Ruiz Veguilla, MD, PhD    0034955013414    mruizveguilla@yahoo.com    Principal Investigator: Miguel Ruiz Veguilla, MD, PhD Less <<
NCT01501695 Tic Disorder ... More >>Tourette Syndrome Chronic Tic Disorder Less << Phase 3 Completed - -
NCT00632645 Huntington Disease Phase 3 Completed - France ... More >> CHU Henri Mondor Creteil, France, 94 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.74mL

0.55mL

0.27mL

13.70mL

2.74mL

1.37mL

27.41mL

5.48mL

2.74mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories